
 OMB APPROVAL

 OMB Number: 3235-0145

 Expires: February 28, 2009

 Estimated average burden
 hours per response 15

UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 SCHEDULE 13D
 UNDER THE SECURITIES EXCHANGE ACT OF 1934
 (AMENDMENT NO. 1) *

Lorus Therapeutics Inc.

 (NAME OF ISSUER)

Common Stock

 (TITLE OF CLASS OF SECURITIES)

544191109

 (CUSIP NUMBER)

Herbert Abramson
 22 St. Clair Avenue East, 18th Floor
 Toronto, Ontario, Canada
 M4T 2S3
 (416) 361-1498

 (NAME, ADDRESS AND TELEPHONE NUMBER OF PERSON AUTHORIZED TO RECEIVE
 NOTICES AND COMMUNICATIONS)

September 17, 2007

 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

NOTE: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See ss.240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 544191109

 1 NAME OF REPORTING PERSON
 S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON

Technifund Inc.
 I.R.S. Identification No. -- Not Applicable

 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
 (a)
 (b)

 3 SEC USE ONLY

4 SOURCE OF FUNDS
WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Ontario, Canada

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 21,115,120
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 21,115,120
	10	SHARED DISPOSITIVE POWER 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
21,115,120

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
9.9%

14 TYPE OF REPORTING PERSON
HC

*See Item 5

CUSIP No. 544191109

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSON

Herbert Abramson
I.R.S. Identification No. -- Not Applicable

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS
PF

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS
2(d) OR 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION
Canadian

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	7	SOLE VOTING POWER 22,879,325
	8	SHARED VOTING POWER 0
	9	SOLE DISPOSITIVE POWER 22,879,325
	10	SHARED DISPOSITIVE POWER 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
22,879,325

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.8%

*See Item 5

This Amendment No. 1 (the "Amendment") amends and supplements the Schedule 13D as filed on July 23, 2007 (the "Schedule 13D"), with respect to the Common Stock of Lorus Therapeutics Inc. (the "Issuer"). Capitalized terms used herein but not defined shall have the meanings ascribed thereto in the Schedule 13D. The Schedule 13D is hereby amended and supplemented as follows:

ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION

The purchase price of the Common Stock reported in this Schedule 13D was CDN\$8,098,846. The Common Stock to which this Schedule 13D relates was purchased using working capital, in respect of shares purchased by Technifund, and personal funds in respect of shares purchased by Abramson.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

(a) As of the close of business on September 17, 2007, the Reporting Persons' beneficial ownership of Common Stock was 22,879,325 shares. Of this amount, 1,764,205 shares of Common Stock were held by Abramson directly and 21,115,120 shares of Common Stock were held by Technifund directly.

(b) The responses of the Reporting Persons to Items 7 through 13 on the cover pages are incorporated herein by reference. All responses reflect the beneficial ownership as of the close of business on September 17, 2007. Abramson exercises sole voting and dispositive power over shares held by him and Technifund. Technifund exercises sole voting and dispositive power over the shares held by it.

(c) Information with respect to all transactions in the Common Stock beneficially owned by the Reporting Persons that were effected during the past sixty days is set forth in Exhibit A attached hereto and incorporated herein by reference.

(d) Other than the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Common Stock reported in this Schedule 13D.

(e) Not applicable.

ITEM 7. MATERIAL TO BE FILED AS EXHIBITS

Exhibit A Schedule of Transactions in Common Stock of the Issuer

Exhibit B Joint Filing Agreement, dated July 31, 2007, by and between Abramson and Technifund*

* Previously filed with the Schedule 13D on July 23, 2007.

SIGNATURES

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

DATE SEPTEMBER 17, 2007

/s/ HERBERT ABRAMSON

Herbert Abramson

TECHNIFUND INC.

By: /s/ HERBERT ABRAMSON

Herbert Abramson
President

EXHIBIT A

SCHEDULE OF TRANSACTIONS IN SHARES OF COMMON STOCK
OF THE ISSUER DURING THE PAST 60 DAYS

TECHNIFUND INC.

DATE OF TRANSACTION	QUANTITY		PRICE/SHARE (\$)
	PURCHASED	(SOLD) (1)	
08/17/07		50,000	\$0.170
08/22/07		6,201	\$0.180
08/22/07		7,519	\$0.190
08/22/07		3,100	\$0.185
08/23/07		7,500	\$0.185
08/23/07		4,000	\$0.190
08/23/07		24,500	\$0.195
08/23/07		28,500	\$0.200
08/23/07		10,000	\$0.205
08/24/07		2,500	\$0.210
08/24/07		112,000	\$0.220
08/24/07		52,000	\$0.225
08/24/07		119,000	\$0.230
08/24/07		10,500	\$0.245

HERBERT ABRAMSON

DATE OF TRANSACTION	QUANTITY		PRICE/SHARE (\$)
	PURCHASED	(SOLD) (1)	
08/22/07		33,799	\$0.180
08/22/07		40,981	\$0.190
08/22/07		16,900	\$0.185
08/27/07		50,000	\$0.230
08/30/07		14,000	\$0.195
08/30/07		349,000	\$0.200
08/30/07		9,000	\$0.205
08/30/07		29,000	\$0.210
09/06/07		49,000	\$0.195
09/06/07		305,000	\$0.200
09/07/07		28,000	\$0.195
09/07/07		75,500	\$0.200
09/07/07		30,000	\$0.205
09/07/07		36,000	\$0.210
09/07/07		3,000	\$0.215
09/07/07		9,000	\$0.215
09/07/07		63,000	\$0.220
09/10/07		500	\$0.220

09/10/07	25,500	\$0.225
09/10/07	106,000	\$0.230
09/11/07	26,500	\$0.220
09/11/07	62,500	\$0.230
09/14/07	142,000	\$0.220
09/14/07	78,000	\$0.230
09/14/07	1,000	\$0.230
09/17/07	99,725	\$0.240

(1) All purchases/sales were effected through open market or privately negotiated transactions.